S-1: Biopharma Faces Delisting Threat Amidst Share Resale and Dilutive Financing

A biopharmaceutical company is registering a significant resale of common stock by existing holders, while grappling with Nasdaq non-compliance issues and a 'going concern' audit opinion, signaling substantial financial challenges.

Summary

• Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing new small molecule antibiotics for difficult-to-treat Gram-positive bacterial infections, including priority pathogens like Clostridioides difficile, MRSA, VRE, and DRSP.
• The company filed an S-1 registration statement for the resale of up to 9,157,596 shares of common stock by selling stockholders, from which the company will not receive any direct proceeds, but will incur expenses.
• If all warrants associated with the resale are exercised for cash, the company could receive approximately $4.0 million.
• Acurx is currently non-compliant with Nasdaq's minimum stockholders' equity requirement ($2.5 million) and minimum bid price requirement ($1.00 per share), facing potential delisting.
• The company received a notice on March 25, 2025, regarding the equity deficiency and had until May 9, 2025, to submit a compliance plan, with a potential 180-day extension.
• A notice on February 24, 2025, indicated non-compliance with the bid price requirement, granting a grace period until August 25, 2025, to regain compliance.
• Recent financing activities include a May 8, 2025, agreement with Lincoln Park Capital Fund, LLC for up to $12.0 million in common stock sales, which could lead to substantial stockholder dilution.
• A March 6, 2025, registered direct offering raised approximately $1.1 million, and a concurrent private placement issued Series F warrants for 8,235,000 shares, subject to future stockholder approval.
• A January 6, 2025, registered direct offering raised approximately $2.5 million, with a concurrent private placement issuing Series E warrants for 2,463,058 shares.
• A warrant inducement transaction on June 17, 2025, involved a selling stockholder exercising 4,445,435 existing warrants at a reduced price of $0.60 per share, in exchange for new Series G-1 and G-2 warrants (totaling 8,890,870 shares) at $0.425 per share, and placement agent warrants for 266,726 shares at $0.75 per share.
• The company's financial statements for the years ended December 31, 2024, and 2023, include an explanatory paragraph from auditors regarding its ability to continue as a 'going concern'.
• As of July 3, 2025, there were 29,627,013 shares of common stock outstanding, with a last reported sale price of $0.473 per share on July 11, 2025.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to severe financial distress, including Nasdaq non-compliance issues that threaten delisting, an auditor's 'going concern' opinion, and ongoing dilutive financing activities. While the company is in a critical area of drug development, its current financial state and market position are highly precarious.

Positives

• Focus on developing a new class of small molecule antibiotics targeting Gram-positive bacteria, including WHO, CDC, and FDA priority pathogens, addressing a critical global health crisis.
• Successfully secured recent capital raises through direct offerings and a purchase agreement with Lincoln Park Capital Fund, LLC, providing potential access to up to $12.0 million in additional capital.
• The warrant inducement transaction generated cash proceeds from the exercise of existing warrants at a reduced price, while also issuing new warrants that could provide future cash if exercised.

Negatives

• The company will not receive any proceeds from the current resale offering of 9,157,596 shares by selling stockholders, only incurring registration expenses.
• Significant dilution risk for existing stockholders due to recent and potential future stock issuances, including the Lincoln Park agreement and various warrant issuances.
• Non-compliance with Nasdaq's minimum stockholders' equity requirement ($2.5 million) and minimum bid price requirement ($1.00 per share), leading to a high risk of delisting.
• The company's auditors included an explanatory paragraph on its ability to continue as a 'going concern' in the financial statements for the years ended December 31, 2024, and 2023, indicating significant financial uncertainty.
• The Series G-2 warrants, representing 2,667,261 shares, are not exercisable without future stockholder approval, which is not guaranteed and could incur substantial costs and management time.
• The common stock's last reported sale price was $0.473 per share, significantly below the Nasdaq minimum bid price requirement of $1.00.

Risks

• Inability to obtain stockholder approval for the exercise of Series G-2 warrants, rendering them valueless and potentially incurring substantial costs and management time.
• Risk of delisting from The Nasdaq Capital Market due to non-compliance with minimum stockholders' equity and minimum bid price requirements, which would negatively affect stock price, liquidity, and future financing ability.
• Substantial dilution to existing stockholders from the May Purchase Agreement with Lincoln Park Capital Fund, LLC, as the company may sell up to $12.0 million of common stock.
• The company's ability to continue as a 'going concern' is uncertain, as indicated by the auditor's explanatory paragraph.
• Inability to obtain and maintain regulatory approval for product candidates (ibezapolstat and others).
• Challenges in successfully commercializing and marketing product candidates if approved.
• Reliance on third-party suppliers, manufacturers, and service providers, and their ability to perform adequately.
• Uncertainty regarding the potential market size, opportunity, and growth for product candidates.
• Difficulty in building sales and marketing capabilities or securing collaborative partners.
• Inability to obtain sufficient funding for operations.
• Risks associated with the initiation, timing, progress, and results of preclinical studies, clinical trials, and R&D programs.
• Uncertainty regarding the timing of anticipated regulatory filings and data availability from clinical trials.
• Inaccuracy of estimates regarding expenses, capital requirements, and needs for additional financing.
• Challenges in retaining key professionals and hiring additional qualified personnel.
• Inability to advance product candidates into and successfully complete clinical trials, or recruit and enroll suitable patients.
• Uncertainty regarding the pricing and reimbursement of product candidates if approved.
• Risks related to the rate and degree of market acceptance of product candidates.
• Challenges in implementing the business model and strategic plans.
• Inability to establish and maintain adequate intellectual property rights.
• Impact of developments relating to competitors and the industry.
• Effects of major public health concerns (e.g., coronavirus, other pandemics) and geopolitical conflicts on clinical trials, business operations, and funding.
• Volatility of the common stock price.

Future Outlook

The company's future outlook is highly dependent on its ability to obtain and maintain regulatory approval for its product candidates, successfully commercialize them, and secure sufficient funding for operations. It aims to advance product candidates through clinical trials and build sales capabilities. The company intends to actively monitor its stock bid price and consider options to regain Nasdaq compliance, potentially including a reverse stock split. It also plans to seek stockholder approval for the issuance of shares upon exercise of Series F and G-2 warrants.

Management Comments

• Intend to actively monitor the bid price of common stock and will consider available options to regain compliance with the Minimum Bid Price Requirement.
• Will use reasonable best efforts to seek Stockholder Approval for issuances of shares of common stock issuable upon exercise of the series G-2 warrants.

Industry Context

Acurx Pharmaceuticals operates in the biopharmaceutical sector, specifically focusing on developing new antibiotics, a critical area given the global crisis of antimicrobial resistance. Its targeting of 'priority pathogens' identified by the WHO, CDC, and FDA aligns with urgent public health needs. The development of new small molecule antibiotics with a Gram-positive selective spectrum (GPSS) that inhibit DNA replication represents a novel approach in a field where new mechanisms of action are highly sought after due to increasing drug resistance.

Corporate Governance

Related Party Transactions

• In the January 6, 2025, Registered Direct Offering, certain affiliate investors (David P. Luci, Robert J. DeLuccia, Carl V. Sailer, Jack H. Dean, James Donohue, and Joseph Scodari, all directors or officers) purchased an aggregate of 167,488 shares of common stock at $1.015 per share.
• In the concurrent January Private Placement, these same affiliate investors received Series E warrants to purchase an aggregate of 167,488 shares of common stock at an exercise price of $0.90 per share.

Stakeholder Impact

• Shareholders face significant dilution from recent and potential future stock issuances (e.g., Lincoln Park agreement, warrant exercises).
• Shareholders are at high risk of value erosion and liquidity issues due to potential delisting from Nasdaq.
• Creditors and potential investors may view the 'going concern' opinion as a significant risk, impacting the company's ability to secure future financing on favorable terms.
• Employees may face uncertainty regarding the company's long-term stability given the financial challenges and delisting risk.

Next Steps

• Regain compliance with Nasdaq's minimum stockholders' equity requirement by submitting an acceptable plan and executing it.
• Regain compliance with Nasdaq's minimum bid price requirement by achieving a closing bid price of $1.00 or more for 10 consecutive business days, potentially through a reverse stock split.
• Obtain stockholder approval for the issuance of shares upon exercise of Series F warrants at the annual meeting on July 17, 2025, or subsequent meetings.
• Obtain stockholder approval for the issuance of shares upon exercise of Series G-2 warrants.
• Potentially sell additional shares of common stock to Lincoln Park Capital Fund, LLC under the May Purchase Agreement to raise capital.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Antibiotics, SEC filing, S-1, Nasdaq, Delisting, Capital raise, Warrants, Stock dilution, Gram-positive bacteria, Clostridioides difficile, MRSA, VRE, DRSP, Going concern, Public offering